Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Navigates Metabolic Syndrome, Finds Link To Liver Disease

Executive Summary

Novartis is using the screening process for the NAVIGATOR study of Diovan and Starlix to connect metabolic syndrome with markers for liver disease, according to data presented at the American Heart Association annual meeting Nov. 16 in Dallas

You may also be interested in...



GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King

Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes

GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King

Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes

Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy

Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor

Topics

UsernamePublicRestriction

Register

PS046598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel